His primary scientific interests are in Internal medicine, Lymphoma, Oncology, Rituximab and Surgery. Jonathan W. Friedberg focuses mostly in the field of Internal medicine, narrowing it down to matters related to Gastroenterology and, in some cases, Febrile neutropenia. He specializes in Lymphoma, namely Follicular lymphoma.
His Follicular lymphoma research includes elements of Prospective cohort study and Chronic lymphocytic leukemia. His biological study spans a wide range of topics, including International Prognostic Index, Diffuse large B-cell lymphoma, Clinical trial, Survival rate and Leukemia. His work deals with themes such as Hematology, Tolerability and Radioimmunotherapy, which intersect with Rituximab.
His scientific interests lie mostly in Internal medicine, Oncology, Lymphoma, Rituximab and Follicular lymphoma. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Surgery and Immunology. Jonathan W. Friedberg interconnects CHOP, Clinical trial, Non-Hodgkin's lymphoma and Hodgkin lymphoma in the investigation of issues within Oncology.
Jonathan W. Friedberg works mostly in the field of Lymphoma, limiting it down to topics relating to Cancer research and, in certain cases, Apoptosis and Proteasome inhibitor, as a part of the same area of interest. His Rituximab study which covers Vincristine that intersects with Prednisone. His Follicular lymphoma research is multidisciplinary, relying on both Radioimmunotherapy, Prospective cohort study and Hazard ratio.
Jonathan W. Friedberg mainly investigates Internal medicine, Oncology, Lymphoma, Rituximab and Hodgkin lymphoma. His study in Internal medicine concentrates on Brentuximab vedotin, Follicular lymphoma, Chemotherapy, Vincristine and Prednisone. His Oncology study combines topics in areas such as Classical Hodgkin lymphoma, Diffuse large B-cell lymphoma, Phases of clinical research and Lenalidomide.
His Lymphoma study also includes fields such as
His main research concerns Internal medicine, Oncology, Rituximab, Lymphoma and Vincristine. Internal medicine is often connected to Gastroenterology in his work. His research in Oncology intersects with topics in Clinical trial, Lenalidomide, EPOCH, Young adult and Hazard ratio.
The Rituximab study combines topics in areas such as Mantle cell lymphoma, Follicular lymphoma, Progression-free survival and Diffuse large B-cell lymphoma. His work carried out in the field of Lymphoma brings together such families of science as Follicular phase, Cancer research, Phases of clinical research, MEDLINE and Treatment options. His Vincristine study also includes
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis.
The New England Journal of Medicine (2017)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg;Jeff Sharman;John Sweetenham;Patrick B. Johnston.
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou;Laurie H. Sehn;Alfred W. Rademaker;Leo I. Gordon.
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo;Michelle Byrtek;Keith L. Dawson;Xiaolei Zhou.
Journal of Clinical Oncology (2015)
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors
Andrea K. Ng;M. V. Patricia Bernardo;Edie Weller;Kendall Backstrand.
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg.
Long-Term Survival and Competing Causes of Death in Patients With Early-Stage Hodgkin’s Disease Treated at Age 50 or Younger
Andrea K. Ng;M. Patricia Bernardo;Edie Weller;Kendall H. Backstrand.
Journal of Clinical Oncology (2002)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge.
The Lancet (2019)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;Victoria Shi.
Journal of Clinical Oncology (2017)
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study
Jonathan W. Friedberg;Philip Cohen;Ling Chen;K. Sue Robinson.
Journal of Clinical Oncology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: